Genescience Pharmaceuticals Co. Ltd. has identified melanocortin MC4 receptor antagonists reported to be useful for the treatment of cachexia, anorexia nervosa, nausea and vomiting, sarcopenia, neuropathic pain, post-traumatic stress disorder and muscle and bone disorders.